Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

EP: 1.Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy

EP: 2.Biological Mechanisms of GIST Resistance and Tumor Heterogeneity

EP: 3.Monitoring Tumor Heterogeneity and Detecting Resistance

EP: 4.Post-Imatinib Progression: Decision Factors and Treatment Options

EP: 5.INVICTUS Trial: Ripretinib in Fourth-Line Setting

EP: 6.INTRIGUE Trial: Key Findings in Second-Line Setting

EP: 7.ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

EP: 8.Managing Adverse Events With Different TKIs

Now Viewing

EP: 9.Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

EP: 10.Practical Recommendations for Community Oncologists

Video content above is prompted by the following:

• The PEAK study is evaluating the combination of bezuclastinib plus sunitinib vs sunitinib alone in second-line GIST. Can you walk us though the preliminary results and comment on how might this combination approach address the challenge of heterogeneous resistance mutations we see after imatinib failure?
• How is this combination approach different from our current sequential TKI approach, and how might this combined targeting strategy address the challenge of heterogeneous resistance mutations we see after imatinib failure?
• What would you consider a clinically meaningful improvement over sunitinib monotherapy that would change your practice?
• Ongoing trials such as INSIGHT are taking a more targeted biomarker-driven approach by focusing on specific molecular subgroups. How might these mutation-specific approaches change our treatment paradigm compared with the traditional line-of-therapy approach?
  Please feel free to highlight any other ongoing trials of note.